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These are the first two volumes of three forming a comprehensive
overview of immunohistochemistry and molecular diagnosis of
Human Carcinomas. Volume 1 deals with lung and breast cancer
and volume 2 colorectal and prostate. Volume 3, which I have not
seen, is apparently available and covers ovary, pancreas and liver.
Volumes 1 and 2 start with some general chapters on techniques
and equipment that are of general relevance and then deal with
their specific cancers in multiple short chapters. Most of these
latter are reviews of immunohistochemical studies of a wide range
of different markers such as mucins, laminin, VEGF and so on.
They all tend to end in the same way that I was able to predict after
reading two or three, that is, this marker may be useful but further
studies are required. Almost nothing other than HER-2 in breast
cancer was an established reagent. Most of the chapters are well
written and illustrated and there is surprisingly little overlap
between them, suggesting careful direction by the editor to his
authors. Most chapters have references up to 2002 and a few even
make 2003. This is pretty good for such a large book, but inevitably
limits its usefulness in such a fast moving field. For example, there
is currently a good deal of interest in quantitative mechanisms for
assessing multitissue arrays, but the latest references here are 2002
and already out of date.
This is a good reference work and probably one of the best of its
kind, but one must question its relevance today. Who is going to
buy these for the office at d110 each (even though I accept this is
good value for such a tome)? Who is going to go down to the
library to consult them when more up to date information is
available at a few keystrokes on the desktop computer (even now
on the laptop on the fly)? Books are still valuable tools for
diagnosis or methods but this is neither. You would not use this to
diagnose breast cancer and you would not get enough detail to
undertake a new technique from the outlines given. Preinternet
such books were vital but are they now obsolete? The publishers
obviously hope not but the sales will tell the true tale.
The preface to Volume 1 written by Dr Hayat is very interesting.
He outlines the objectives of this book as discussion of the various
procedures and techniques and of the role of molecular pathology
in achieving correct diagnosis and therapy. The first the books
handle quite well but the second is problematical. Clinical practice,
he says, has lagged behind molecular genetics. One reason for this
is that it needs to be handled by clinician – scientists or academic
clinicians. There is a dearth of these because of poor pay. Amen to
that we might all say but are we diagnosticians such dullards? Are
we short-changing our patients because of our Luddite inability to
implement new tests. Well on reading these two volumes, I could
not see a test that works that we are not using generally in the UK
in practice, and I imagine that holds generally in the developed
world. When antibodies are needed we use them and when genetic
testing is important as in acute leukaemia we implement it. I
sometimes think we do a disservice when we preach on about how
backward are our clinical colleagues. Most of the studies in these
books, fun as they may have been to perform, have no currently
recognisable diagnostic value and probably never will. We should
not forget that most of our research is not useful; we just do not yet
know how to identify in advance those few kernels of gold.
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